Clinical Research Directory

Inclusion Criteria: * Age 18 years or older on date of enrollment. * Diagnosed within the past six months with histologically proven, localized adenocarcinoma of prostate determined via transrectal ultrasonography and biopsy of at least 10 prostate sites. * Received Prolaris testing and a resulting CCR score from the diagnostic biopsy sample as standard of care. * Can be monitored for disease progression according to standard of care (e.g., current NCCN guidelines). Exclusion Criteria: * Estimated life expectancy \< 10 years. * Clinical evidence of metastasis or lymph node involvement. * Received pelvic radiation prior to biopsy. * Received androgen deprivation therapy (ADT) prior to biopsy; however, 5 alpha- reductase inhibitor (5-ARI) use is permitted. * Plan to use PrCa-specific prognostic testing other than PSA for treatment decision making during Active Surveillance. * Currently participating in an interventional clinical trial. * Unable to provide routine clinical informed consent.